The Latest Analyst Ratings for Guardant Health
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Preview: Guardant Health’s Earnings
Guardant Health (NASDAQ:GH) is set to give its latest quarterly earnings report on Thursday, 2023-08-03. Here’s what investors…
Guardant Health Receives First Commercial Payor Coverage For Guardant Reveal Test From Blue Cross And Blue Shield Of Louisiana
First blood-only liquid biopsy test for molecular residual disease now covered for serial testing in patients with stage II or III colorectal cancer
Test used after surgery or curative treatment to inform physician
Guardant Health Announces Reimbursement Approval Of Guardant360 CDX Liquid Biopsy Test In Japan
Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan
Guardant Health, Inc.
Benzinga’s Top Ratings Upgrades, Downgrades For May 26, 2023
Upgrades RBC Capital upgraded the previous rating for New Relic Inc (NYSE:NEWR) from Sector Perform to Outperform. For…
Analyst Ratings for Guardant Health
Within the last quarter, Guardant Health (NASDAQ:GH) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Guardant Health Shares Move Lower On $350M Public Offering: The Details
Guardant Health Inc (NASDAQ: GH) shares are trading lower Tuesday after the company announced an offering.
What 11 Analyst Ratings Have To Say About Guardant Health
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Guardant Health presents Additional Information From ECLIPSE Study At 2023 Digestive Disease Week On The Performance Of Shield Blood Test
Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening